Influence of MRIs performed in a 6-week interval on the histopathological detection of prostate cancer with different PIRADS classifications: A real-world data analysis.

T Tim Nestler (Department of Urology, Federal Armed Forces Hospital Koblenz, Koblenz, Germany) J Justine Schoch (Department of Urology, Federal Armed Forces Hospital Koblenz, Koblenz, Germany) V Viola Düring (Department of Urology, Federal Armed Forces Hospital Koblenz, Koblenz, Germany) M Michael Wiedmann (Department of Urology, Federal Armed Forces Hospital Koblenz, Koblenz, Germany) D Daniel Overhoff (Institute of Diagnostic and Interventional Radiology, Federal Armed Forces Hospital Koblenz, Koblenz, Germany) D Daniel Dillinger (Institute of Diagnostic and Interventional Radiology, Federal Armed Forces Hospital Koblenz, Koblenz, Germany) S Stephan Waldeck H Hans Schmelz (Department of Urology, Federal Armed Services Hospital Koblenz, Koblenz, Germany)

Abstract

334 Background: In the early phases of MRI-guided prostate biopsies, it was often necessary to perform an additional in-house multiparametric MRI after an external MRI to accurately assess lesions for biopsy. This study aims to evaluate the consistency of lesion identification and the associated clinical and histological outcomes at a high-volume tertiary care center performing over 500 biopsies annually. Methods: This analysis included real-world data from 111 patients treated between 2018 and 2022. Each patient underwent two multiparametric MRI scans of the prostate at different institutions, with a median interval of 42 days [32–52] between scans. An MRI-fused biopsy followed 7 days [4–10] after the second MRI. Data were analyzed using the Chi-square test. Results: The PIRADS scores for index lesions on the in-house MRI were as follows: PIRADS V in 33.3% (n=37), PIRADS IV in 49.5% (n=55), PIRADS III in 12.6% (n=14), and PIRADS II in 4.5% (n=5) (Table 1). Most lesions were located in the peripheral zone of the prostate (68.8%, n=75). Cancer detection rates for randomized and/or targeted biopsies were 91.9% (n=34) for PIRADS V, 65.5% (n=36) for PIRADS IV, 21.4% (n=3) for PIRADS III, and 20% (n=1) for PIRADS II. Clinically significant prostate cancer (ISUP > 1) was detected in 91.9% (n=34) of PIRADS V, 60% (n=33) of PIRADS IV, and 21.4% (n=3) of PIRADS III lesions. Overall, malignant histology was found in 64.9% (n=72) of targeted lesions and 59.5% (n=66) of randomized biopsies. A median of 7 [5.5–8.5] biopsies were taken per lesion, with an additional 13 [11–15] randomized biopsies. In the initial external MRI, 18% (n=20) of patients were assigned a higher PIRADS category, while 10.8% (n=12) were had a lower score (p<0.001). The biopsy plan was adjusted for 57 patients (51.4%) based on the findings of the second MRI. However, given the cancer detection rates in both targeted and randomized biopsies, it is likely that all cancers would have been detected regardless of these adjustments. Conclusions: Although PIRADS classifications varied slightly between the two MRI scans performed six weeks apart, and biopsy plans were adjusted in about half of the cases, all cancers would likely have been identified. The six-week interval between MRI scans does not appear to significantly affect biopsy accuracy. PIRADS classification comparison of internal and external MRI. External MRI PIRADS II PIRADS III PIRADS IV PIRADS V All Internal MRI PIRADS II 0 40% (2) 40% (2) 20% (1) 5 PIRADS III 0 28.6% (4) 57.1% (8) 14.3% (2) 14 PIRADS IV 0 9.1% (5) 81.8% (45) 9.1% (5) 55 PIRADS V 0 2.7% (1) 16.2% (6) 81.1% (30) 37 All 0 12 60 39

Article Details

Volume / Issue Vol. 43, Issue 5_suppl
Published February 10, 2025
Pages 334-334
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (8)

T

Tim Nestler

Department of Urology, Federal Armed Forces Hospital Koblenz, Koblenz, Germany

J

Justine Schoch

Department of Urology, Federal Armed Forces Hospital Koblenz, Koblenz, Germany

V

Viola Düring

Department of Urology, Federal Armed Forces Hospital Koblenz, Koblenz, Germany

M

Michael Wiedmann

Department of Urology, Federal Armed Forces Hospital Koblenz, Koblenz, Germany

D

Daniel Overhoff

Institute of Diagnostic and Interventional Radiology, Federal Armed Forces Hospital Koblenz, Koblenz, Germany

D

Daniel Dillinger

Institute of Diagnostic and Interventional Radiology, Federal Armed Forces Hospital Koblenz, Koblenz, Germany

S

Stephan Waldeck

H

Hans Schmelz

Department of Urology, Federal Armed Services Hospital Koblenz, Koblenz, Germany